Stealth BioTherapeutics

Today, Stealth BioTherapeutics announces a commercial and pipeline update. Learn more in our press release: https://bit.ly/4t8NqiB

The future of biotechnology will be defined by the choices we make today – on policy, investment, and the ecosystem needed for innovation to thrive. Fight of Our Lives brings forward the voices and stories that demonstrate why continued leadership in biotech matters. Stealth BioTherapeutics is proud to be a part of this effort alongside Biotechnology Innovation Organization (BIO). Learn more: https://lnkd.in/ePEStXYp #FightOfOurLives

Stealth BioTherapeutics is pleased to announce we will be presenting at the upcoming Association for Research in Vision and Ophthalmology (ARVO) annual meeting! Learn more in the press release here: https://bit.ly/4u6LsQv #ARVO2026 #MitochondrialMedicine

Stealth is extremely excited to announce the appointment of David A. Brown, Ph.D., as Chief Scientific Officer to help advance our pioneering work in mitochondrial medicine! Read the full press release here: https://bit.ly/41Syzxl

Today, April 5th, marks Barth syndrome Awareness Day!   The Barth syndrome community is one that embodies strength, resilience, and compassion. Patients, families, caregivers, and advocates face daily challenges with courage while continuing to push for greater awareness, answers, and progress. Their voices are driving change, and their advocacy is making a difference. At Stealth we are inspired by this community every day.    Today is a reminder that awareness matters, but so does action. We stand with the Barth syndrome community in amplifying their voices and advancing the science that this community deserves. #BarthSyndromeAwareness

Stealth BioTherapeutics is pleased to announce an award from the Business Engagement Fund from the UK Research and Innovation Medical Research Council to support a new collaborative research project among the Mary Lyon Centre at MRC Harwell, the MRC National Mouse Genetics Network, and academic leaders from UCL. Please read the press release here: https://bit.ly/4rSNwub

Today is #RareDiseaseDay, a moment to recognize the millions of people worldwide living with rare conditions and the families, clinicians, and scientists committed to changing what’s possible. Mitochondrial diseases are rare, but their impact is profound. At Stealth BioTherapeutics, our work is driven by one goal: to lead the development of mitochondrial medicine to improve the lives of patients with diseases involving mitochondrial dysfunction. Today, and every day, we stand with the rare disease community to #ShowOurStripes and remain committed to advancing research where it’s needed most. #MitochondrialDisease #PatientsFirst

Did you know the inner mitochondrial membrane is enriched with cardiolipin, a unique phospholipid that is essential for maintaining mitochondrial structure and function? Stealth is evaluating the potential protective effects of our investigational, cardiolipin-targeted compound in human cardiac muscle. Stop by poster #2036 at Keystone Symposia on Molecular & Cellular Biology to learn more about the development of this therapeutic as a potential treatment for heart disease. https://bit.ly/4pvGb2v #keystonesymposia #mitochondria #heartfailure

We are just days away from Dr. Barakat taking the stage at Hawaiian Eye & Retina 2026 to share a deeper analysis of the ReCLAIM-2 study. His presentation explores how baseline patient characteristics and imaging biomarkers may help reveal which individuals experience meaningful visual function gain. This session provides a closer look at the nuances in dry AMD that shape early patient identification and future therapeutic insights. Session Details Date: January 19, 2026 Time: 10:01 AM to 10:07 AM Title: ReCLAIM-2: A Deeper Look Into Baseline Patient Populations Session: Waves of Discovery: Retina Abstract Presentations #HawaiianEye2026 #Retina #Ophthalmology #ClinicalInsights #ImagingBiomarkers #ReCLAIM2 #VisionScience

Dr. Mark Barakat, MD will take the stage at Hawaiian Eye 2026 to share a deeper analysis of the ReCLAIM-2 study. His presentation explores how baseline patient characteristics and imaging biomarkers may help reveal which individuals experience meaningful visual function gain. This session provides a closer look at the nuances in dry AMD that shape early patient identification and future therapeutic insights. 📌 Session Details Date: January 19, 2026 Time: 10:01 AM to 10:07 AM HAST Title: ReCLAIM-2: A Deeper Look Into Baseline Patient Populations Session: Waves of Discovery: Retina Abstract Presentations #HawaiianEye2026 #Retina #Ophthalmology #ClinicalInsights #dryAMD #ImagingBiomarkers #ReCLAIM2 #VisionScience